Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

Stocks are pricey—but there are values to be had. Learn more about our panelists’ picks in this week’s Roundtable installment.

Health care, ride sharing, and the emerging world of YouTube entertainers are among industries leading investors have picked ...

US stocks gave up early gains to end mixed. Investors await key consumer inflation data and the start of earnings season on ...

Asit Sharma: Well, I am chilling with the fam, but in an alternate universe, Ricky, I'm showing up with a few beers and a pack of cards at your house to spend ... drug space after a monster 2022, 2023 ...

A strong Dec. jobs report triggered a $1T market sell-off, highlighting investor fears of rising inflation. Read why I'm ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.